ArticleCardiology journal2026
Seven-day ECG Holter vs. 14-day event Holter in the detection of life-threatening ventricular arrhythmias, new atrial fibrillation, and silent ischemia among heart failure patients from social exclusion regions.
Article in Cardiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt was sought to compare the effectiveness of two methods 7-day ECG Holter or 14-day event-Holter monitoring in detection of arrythmias and ischemia in a heart failure (HF) population far from academic centers treated by a primary care physician under cardiologist supervision.
methodsIn the prospective, non-randomized, 3-month pilot program carried out between June and December 2023 recruited were 429 HF patients from villages and small cities in 14 primary care units, far from academic centers. Of them, 124 (28.9%) patients were additionally monitored by either 7-day ECG Holter (7H-group) or 14-day event Holter (14eH-group). The cumulative percentage of patients with non-sustained ventricular tachycardia, new atrial fibrillation or ischemic changes was a primary composite endpoint.
resultsOf 126 patients, 54 (43.5%) were monitored by 7-day ECG Holter while 70 (56.5%) by 14-day event Holter. At baseline, there were no significant differences between 7H- vs. 14eH-group in terms of demographics and cardiovascular risk factors. A history of PCI was more frequent in 7H- vs. 14eH-group (33 vs. 15%, p = 0.039). The cumulative percentage of the primary composite endpoint was significantly higher in 7H- vs. 14eH-group (24 vs. 2.9%, p < 0.001) and was driven by silent ischemia. The number of therapeutic interventions, including introduction of an oral anticoagulant or coronary angioplasty was numerically higher in 7H- vs. 14eH-group (11.1 vs. 4.3%, p = 0.27).
conclusionsIn this pilot study, 7-day ECG Holter was more effective in detection of non-sustained ventricular tachycardia, new atrial fibrillation or ischemic changes than 14-day event-Holter in HF patients in social exclusion regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.